❭ Research by medical division ❭ Cancer Medicine ❭ Institute for Cancer Research ❭ Dept. of Tumor Biology ❭ Metastasis Biology and Experimental Therapeutics [Mælandsmo] ❭ Research interests

Our major areas of interest are:

Treatment Resistance and Metastasis-Involved Mechanisms

  • Cellular plasticity 
    • Breast cancer and melanoma
    • Prostate cancer
  • Metastasis-associated proteins
  • Immune checkpoint protein B7-H3 as novel therapeutic target in cancer

Word cloud from articles published by the group the past 10 years

Experimental Cancer Therapy

  • Nanoparticle-based drug delivery
  • Breast cancer
  • Prostate cancer

Precision Cancer Medicine

  • Clinical studies in breast cancer
  • Clinical studies in melanoma
  • Metaction
  • Biomarker studies in clinical cohorts
    • Breast cancer biomarkers
    • Biomarkers in melanoma - The MelMet project
    • Brain metastasis
    • Prostate cancer biomarkers
 
Scroll to top

Home Dept. of Tumor Biology Metastasis Biology and Experimental Therapeutics [Mælandsmo]

  • Group members
  • Research interests
  • Publications
  • Links

Recent publications

Hogstrom L, Laurinavicius A, Alvarez MG, Nakken S, Guldvik IJ, Sanchez CM, Papadodima O, Voutetakis K, Mæhle PM, Zerbe N, Šekerija M, Fullaondo A, Hovig E (2026)
European cancer data sharing: Analyses of an international survey
Int J Med Inform, 218, 106544
DOI 10.1016/j.ijmedinf.2026.106544, PubMed 42284829

Nunes-Xavier CE, Rodríguez-Ramos A, Pulido R (2026)
β-catenin at the crossroads of cancer and neurodevelopment
Trends Cancer (in press)
DOI 10.1016/j.trecan.2026.05.001, PubMed 42215419

Azimzade Y, Haugen MH, Kristensen VN, Frigessi A, Köhn-Luque A (2026)
Explainable machine learning-guided integrated multiomics analysis reveals macrophage-driven immune suppression in breast cancer
Nat Commun (in press)
DOI 10.1038/s41467-026-73617-9, PubMed 42185288



More publications

Oslo University Hospital is a part of Southern and Eastern Norway Regional Health Authority.

Webmaster for research pages: Trond Olav Berg

Cookie policy

Accessibility statement (in Norwegian)